Literature DB >> 25746630

Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma.

Ama-Tawiah Essilfie1, Jay C Horvat1, Richard Y Kim1, Jemma R Mayall1, James W Pinkerton1, Emma L Beckett1, Malcolm R Starkey1, Jodie L Simpson1, Paul S Foster1, Peter G Gibson1, Philip M Hansbro1.   

Abstract

BACKGROUND: Steroid-insensitive endotypes of asthma are an important clinical problem and effective therapies are required. They are associated with bacterial infection and non-eosinophilic inflammatory responses in the asthmatic lung. Macrolide therapy is effective in steroid-insensitive endotypes, such as non-eosinophilic asthma. However, whether the effects of macrolides are due to antimicrobial or anti-inflammatory mechanisms is not known.
OBJECTIVE: To determine and assess the efficacy of macrolide (ie, clarithromycin) and non-macrolide (ie, amoxicillin) antibiotic treatments in experimental models of infection-induced, severe, steroid-insensitive neutrophilic allergic airways disease (SSIAAD), compared with steroid-sensitive AAD and to delineate the antimicrobial and anti-inflammatory effects of macrolide therapy.
METHODS: We developed and used novel mouse models of Chlamydia and Haemophilus lung infection-induced SSIAAD. We used these models to investigate the effects of clarithromycin and amoxicillin treatment on immune responses and airways hyper-responsiveness (AHR) in Ova-induced, T helper lymphocyte (Th) 2 -associated steroid-sensitive AAD and infection-induced Th1/Th17-associated SSIAAD compared with dexamethasone treatment.
RESULTS: Clarithromycin and amoxicillin had similar antimicrobial effects on infection. Amoxicillin did attenuate some features, but did not broadly suppress either form of AAD. It did restore steroid sensitivity in SSIAAD by reducing infection. In contrast, clarithromycin alone widely suppressed inflammation and AHR in both steroid-sensitive AAD and SSIAAD. This occurred through reductions in Th2 responses that drive steroid-sensitive eosinophilic AAD and tumour necrosis factor α and interleukin 17 responses that induce SSIAAD.
CONCLUSIONS: Macrolides have broad anti-inflammatory effects in AAD that are likely independent of their antimicrobial effects. The specific responses that are suppressed are dependent upon the responses that dominate during AAD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Allergic lung disease; Asthma; Bacterial Infection; Respiratory Infection

Mesh:

Substances:

Year:  2015        PMID: 25746630     DOI: 10.1136/thoraxjnl-2014-206067

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  39 in total

Review 1.  The Microbiome and the Respiratory Tract.

Authors:  Robert P Dickson; John R Erb-Downward; Fernando J Martinez; Gary B Huffnagle
Journal:  Annu Rev Physiol       Date:  2015-11-02       Impact factor: 19.318

2.  MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD.

Authors:  Alan C-Y Hsu; Kamal Dua; Malcolm R Starkey; Tatt-Jhong Haw; Prema M Nair; Kristy Nichol; Nathan Zammit; Shane T Grey; Katherine J Baines; Paul S Foster; Philip M Hansbro; Peter A Wark
Journal:  JCI Insight       Date:  2017-04-06

Review 3.  Novel approaches to the management of noneosinophilic asthma.

Authors:  Neil C Thomson
Journal:  Ther Adv Respir Dis       Date:  2016-02-28       Impact factor: 4.031

4.  The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model.

Authors:  A G Jarnicki; H Schilter; G Liu; K Wheeldon; A-T Essilfie; J S Foot; T T Yow; W Jarolimek; P M Hansbro
Journal:  Br J Pharmacol       Date:  2016-10-12       Impact factor: 8.739

5.  CpG oligodeoxynucleotides attenuate RORγt-mediated Th17 response by restoring histone deacetylase-2 in cigarette smoke-exposure asthma.

Authors:  Hongtao Li; Qimei Ye; Yusen Lin; Xuena Yang; Xiaoling Zou; Hailing Yang; Wenbin Wu; Ping Meng; Tiantuo Zhang
Journal:  Cell Biosci       Date:  2021-05-20       Impact factor: 7.133

6.  IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis.

Authors:  Malcolm R Starkey; Maximilian W Plank; Paolo Casolari; Alberto Papi; Stelios Pavlidis; Yike Guo; Guy J M Cameron; Tatt Jhong Haw; Anthony Tam; Ma'en Obiedat; Chantal Donovan; Nicole G Hansbro; Duc H Nguyen; Prema Mono Nair; Richard Y Kim; Jay C Horvat; Gerard E Kaiko; Scott K Durum; Peter A Wark; Don D Sin; Gaetano Caramori; Ian M Adcock; Paul S Foster; Philip M Hansbro
Journal:  Eur Respir J       Date:  2019-07-18       Impact factor: 16.671

7.  Fibulin-1c regulates transforming growth factor-β activation in pulmonary tissue fibrosis.

Authors:  Gang Liu; Marion A Cooley; Andrew G Jarnicki; Theo Borghuis; Prema M Nair; Gavin Tjin; Alan C Hsu; Tatt Jhong Haw; Michael Fricker; Celeste L Harrison; Bernadette Jones; Nicole G Hansbro; Peter A Wark; Jay C Horvat; W Scott Argraves; Brian G Oliver; Darryl A Knight; Janette K Burgess; Philip M Hansbro
Journal:  JCI Insight       Date:  2019-07-25

Review 8.  Autoinflammatory disease in the lung.

Authors:  Thomas Scambler; Jonathan Holbrook; Sinisa Savic; Michael F McDermott; Daniel Peckham
Journal:  Immunology       Date:  2018-04-19       Impact factor: 7.397

9.  Allergen-encoding bone marrow transfer inactivates allergic T cell responses, alleviating airway inflammation.

Authors:  Jane Al-Kouba; Andrew N Wilkinson; Malcolm R Starkey; Rajeev Rudraraju; Rhiannon B Werder; Xiao Liu; Soi-Cheng Law; Jay C Horvat; Jeremy F Brooks; Geoffrey R Hill; Janet M Davies; Simon Phipps; Philip M Hansbro; Raymond J Steptoe
Journal:  JCI Insight       Date:  2017-06-02

Review 10.  Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators.

Authors:  Madhur D Shastri; Wai Chin Chong; Kamal Dua; Gregory M Peterson; Rahul P Patel; Malik Q Mahmood; Murtaza Tambuwala; Dinesh K Chellappan; Nicole G Hansbro; Shakti D Shukla; Philip M Hansbro
Journal:  Inflammopharmacology       Date:  2020-11-05       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.